Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNY3 pseudogene 2 (RNY3P2)** is a human pseudogene related to the RNY3 (Ro-associated Y3 RNA) gene, which encodes a small non-coding Y-RNA; as a pseudogene, RNY3P2 is a non-functional genetic element formed through mutation or duplication and does not produce a functional protein or known regulatory RNA. Pseudogenes in general can sometimes regulate their cognate genes post-transcriptionally (e.g., via antisense transcripts, miRNA competition, or RNA-binding protein interactions), but there is no evidence in current sources that RNY3P2 has any known biological function, therapeutic relevance, or clinical impact[2][6]. The parental RNY3 gene is involved in DNA replication and RNA quality control and has been studied in immune response and DNA replication contexts[1][5]. Over 1,000 Y-RNA pseudogenes exist in the human genome, and most do not have known functions[5]. No drugs, mechanisms of action, biomarker roles, or specific disease links are assigned to RNY3P2, and there is no evidence it is a relevant therapeutic or biological target.\n\n**Key notes on accuracy and nomenclature:**\n- There is no evidence that RNY3P2 is a functional molecule, a therapeutic target, a receptor, enzyme, or bona fide biological regulator[1][2][5]; it is a non-functional pseudogene.\n- Reason for **is_incorrect: true** — the request treats RNY3P2 as a discrete, meaningful therapeutic target, but available data show it is a non-functional pseudogene and not a receptor, enzyme, or recognized drug target[2][6]. If you intended to ask about "RNY3" or a different functional target, please clarify.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNY3 pseudogene 2 (RNY3P2).